MCC
GRCE

Money Concepts Capital’s Grace Therapeutics GRCE Stock Holding History

Money Concepts Capital’s Portfolio GRCE Stock Details GRCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-31
Closed -$94 – 3005
2022
Q4 		$94 Buy
+31
New +$91 ﹤0.01% 3155

Other funds holding GRCE

TPCW
TD Private Client Wealth New York $4.82B AUM 15.21% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
ASN
Advisory Services Network Atlanta, Georgia $7.52B AUM 29.01% 1-Year Est. Return

Money Concepts Capital's GRCE Position: Q1 2023 in Review

Money Concepts Capital sold out of Grace Therapeutics (GRCE) in Q1 2023, closing a stake of 31 shares — an estimated $94 sold.

Money Concepts Capital first reported a position in GRCE in Q4 2022 and held it in 1 quarter. The position peaked at $94 in Q4 2022. 13 funds tracked by Wall St. Rank hold GRCE as of Q1 2023.

  • Money Concepts Capital reported no remaining Grace Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Money Concepts Capital sold 31 Grace Therapeutics shares in Q1 2023, an estimated $94.
  • Money Concepts Capital first reported a position in Grace Therapeutics in Q4 2022 and held it in 1 quarter.
  • Money Concepts Capital's Grace Therapeutics position peaked at $94 in Q4 2022.
  • 13 funds tracked by Wall St. Rank held Grace Therapeutics as of Q1 2023.

Based on Money Concepts Capital's 13F filing for Q1 2023, filed 1 May 2023.